HomeCompareCARA vs MCD

CARA vs MCD: Dividend Comparison 2026

CARA yields 37.59% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CARA wins by $124.7K in total portfolio value
10 years
CARA
CARA
● Live price
37.59%
Share price
$5.32
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$203.2K
Annual income
$32,602.95
Full CARA calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — CARA vs MCD

📍 CARA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCARAMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CARA + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CARA pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CARA
Annual income on $10K today (after 15% tax)
$3,195.49/yr
After 10yr DRIP, annual income (after tax)
$27,712.51/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, CARA beats the other by $5,418.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CARA + MCD for your $10,000?

CARA: 50%MCD: 50%
100% MCD50/50100% CARA
Portfolio after 10yr
$140.9K
Annual income
$29,415.32/yr
Blended yield
20.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

CARA
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$14.50
+172.6% upside vs current
Range: $1.00 — $30.00
Altman Z
-4.0
Piotroski
1/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CARA buys
0
MCD buys
0
No recent congressional trades found for CARA or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCARAMCD
Forward yield37.59%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$203.2K$78.5K
Annual income after 10y$32,602.95$26,227.70
Total dividends collected$150.0K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$14.50$351.76

Year-by-year: CARA vs MCD ($10,000, DRIP)

YearCARA PortfolioCARA Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$14,459$3,759.40$10,815$334.85+$3.6KCARA
2$20,552$5,080.25$11,826$491.71+$8.7KCARA
3$28,739$6,748.40$13,123$730.06+$15.6KCARA
4$39,570$8,819.34$14,853$1,100.07+$24.7KCARA
5$53,689$11,348.75$17,257$1,690.61+$36.4KCARA
6$71,837$14,390.67$20,752$2,667.01+$51.1KCARA
7$94,862$17,995.60$26,103$4,354.83+$68.8KCARA
8$123,711$22,208.66$34,794$7,437.78+$88.9KCARA
9$159,438$27,067.93$49,926$13,461.60+$109.5KCARA
10$203,202$32,602.95$78,550$26,227.70+$124.7KCARA

CARA vs MCD: Complete Analysis 2026

CARAStock

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Full CARA Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this CARA vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CARA vs SCHDCARA vs JEPICARA vs OCARA vs KOCARA vs MAINCARA vs YUMCARA vs QSRCARA vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.